Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine transdermal patch - Scilex Holding

Next Previous
Drug Profile

Lidocaine transdermal patch - Scilex Holding

Alternative Names: Lidocaine 1.8% patch - Scilex Holding; Lidocaine 5.4% patch - Scilex Holding; Lidocaine topical system - Scilex Holding; Lidocaine topical system 1.8% - Scilex Holding; Lidocaine topical system 5.4% - Scilex Holding; SP-103; ZTlido

Latest Information Update: 08 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scilex Pharmaceuticals
  • Developer Scilex Holding; Scilex Pharmaceuticals
  • Class Acetanilides; Amines; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postherpetic neuralgia
  • Phase II Back pain

Most Recent Events

  • 26 Mar 2025 First generic equivalent approved for Postherpetic neuralgia in USA
  • 06 Jan 2025 Chemical structure information added.
  • 30 Oct 2024 Scilex Holding Company completes end of phase II meeting with US FDA for SP-103 for NDA submission for Back pain

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top